Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Multicoin co-founder is accused of having a close relationship with SBF, Dragonfly partner claims lack of concrete evidence

Multicoin co-founder is accused of having a close relationship with SBF, Dragonfly partner claims lack of concrete evidence

Bitget2024/12/29 21:27

The founder of The Daily Gwei, Anthony Sassano, accuses Multicoin Capital co-founder Kyle Samani of repeatedly lying for profit and having a close relationship with SBF, participating in multiple "scams", questioning his unawareness of FTX's anomalies. In response to this, Dragonfly Capital partner Haseeb Qureshi said that the claim of collusion with SBF requires solid evidence, and Multicoin itself also suffered losses due to FTX's bankruptcy. He also recognizes Kyle's investment ability, saying that he dares to bet on unpopular projects and is one of the few contrarian investors in the crypto field, but his personal style is controversial.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss